Sysmex Corporation
Notice Regarding Recognition of Impairment Loss (Consolidated Financial Statements) and Revision of Full-Year Earnings Forecast for Fiscal Year Ending March 2026
An impairment loss of 11,557 million yen was recorded for the fiscal year ending March 2026. Operating income has been revised down by 17.7% from the previous forecast to 51,000 million yen, and net income attributable to owners of parent has been revised down by 14.6% to 35,000 million yen.
Key Figures
- Impairment Loss (Consolidated): 11,557 million yen
- Operating Income (Revised): 51,000 million yen (Down 17.7% from previous forecast)
- Net Income Attributable to Owners of Parent (Revised): 35,000 million yen (Down 14.6% from previous forecast)
AI要約
Regarding Recognition of Impairment Loss
In the fourth quarter of the fiscal year ending March 2026, Sysmex Corporation conducted impairment tests on goodwill of its consolidated subsidiaries and, considering future cash flow forecasts and changes in the business environment, recorded an impairment loss of 11,557 million yen under other operating expenses. The goodwill affected relates to Sysmex Partec GmbH, Oxford Gene Technology IP Limited, and Sysmex Astrego AB.
Revision of Full-Year Earnings Forecast for Fiscal Year Ending March 2026
Following the recognition of the impairment loss, the full-year consolidated earnings forecast for the fiscal year ending March 2026 has been revised. Net sales remain unchanged from the previous forecast of 500,000 million yen; however, operating income is revised down from 62,000 million yen to 51,000 million yen, a decrease of 17.7%, income before income taxes is revised down from 59,000 million yen to 49,000 million yen, a decrease of 16.9%, and net income attributable to owners of parent is revised down from 41,000 million yen to 35,000 million yen, a decrease of 14.6%. There are no changes to the dividend forecast.
Sysmex Corporation
Company overview · Stock price · Financial data · All IR
